|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.64 USD | -3.02% |
|
-9.16% | +5.67% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -30.1 | -17.86 | -20.86 | -15.87 | -12.16 | |||||
Return on Total Capital | -33.87 | -20.53 | -25.07 | -19.53 | -14.83 | |||||
Return On Equity % | -55.27 | -36.55 | -36.34 | -31.41 | -22.56 | |||||
Return on Common Equity | -55.27 | -36.55 | -36.34 | -31.41 | -22.56 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -333.47 | -67.61 | -35.6 | 4.17 | 10.47 | |||||
SG&A Margin | 151.64 | 120.43 | 105.58 | 74.87 | 60.33 | |||||
EBITDA Margin % | -480.61 | -184.21 | -137.8 | -67.74 | -46.6 | |||||
EBITA Margin % | -484.76 | -187.81 | -140.92 | -69.91 | -48.58 | |||||
EBIT Margin % | -485.1 | -188.04 | -141.19 | -70.71 | -49.86 | |||||
Income From Continuing Operations Margin % | -488.16 | -206.14 | -125.46 | -64.44 | -38.15 | |||||
Net Income Margin % | -488.16 | -206.14 | -125.46 | -64.44 | -38.15 | |||||
Net Avail. For Common Margin % | -488.16 | -206.14 | -125.46 | -64.44 | -38.15 | |||||
Normalized Net Income Margin | -298.77 | -126.24 | -81.41 | -39.32 | -23.98 | |||||
Levered Free Cash Flow Margin | -261.72 | -133.21 | -35.77 | -82.72 | -20.1 | |||||
Unlevered Free Cash Flow Margin | -261.72 | -133.21 | -35.77 | -82.54 | -19.44 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.1 | 0.15 | 0.24 | 0.36 | 0.39 | |||||
Fixed Assets Turnover | 2.77 | 3.19 | 3.65 | 5.78 | 6.77 | |||||
Receivables Turnover (Average Receivables) | 4.81 | 4.16 | 4.68 | 5.16 | 4.43 | |||||
Inventory Turnover (Average Inventory) | 38.98 | 14.25 | 9.46 | 9.03 | 7.19 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.78 | 8.04 | 4.63 | 3.51 | 2.45 | |||||
Quick Ratio | 7.59 | 7.56 | 4.29 | 2.9 | 1.94 | |||||
Operating Cash Flow to Current Liabilities | -2.85 | -2.63 | -0.98 | -0.72 | -0.36 | |||||
Days Sales Outstanding (Average Receivables) | 75.84 | 87.74 | 77.94 | 70.97 | 82.37 | |||||
Days Outstanding Inventory (Average Inventory) | 9.36 | 25.61 | 38.57 | 40.54 | 50.77 | |||||
Average Days Payable Outstanding | 54.58 | 93.98 | 87.12 | 103.71 | 99.04 | |||||
Cash Conversion Cycle (Average Days) | 30.63 | 19.36 | 29.39 | 7.8 | 34.1 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.13 | 1.95 | 1.9 | 18.25 | 31.34 | |||||
Total Debt / Total Capital | 1.11 | 1.91 | 1.87 | 15.43 | 23.86 | |||||
LT Debt/Equity | 0.7 | 1.28 | 1.01 | 1.63 | 1.87 | |||||
Long-Term Debt / Total Capital | 0.69 | 1.25 | 0.99 | 1.38 | 1.42 | |||||
Total Liabilities / Total Assets | 14.29 | 14.31 | 23.18 | 29.08 | 38.97 | |||||
EBIT / Interest Expense | - | - | - | -125.16 | -44.05 | |||||
EBITDA / Interest Expense | - | - | - | -116.02 | -39.37 | |||||
(EBITDA - Capex) / Interest Expense | - | - | - | -118.53 | -40.93 | |||||
Total Debt / EBITDA | -0.02 | -0.05 | -0.04 | -0.59 | -1.09 | |||||
Net Debt / EBITDA | 2.03 | 2.55 | 2.21 | 2.39 | 2.27 | |||||
Total Debt / (EBITDA - Capex) | -0.02 | -0.05 | -0.04 | -0.57 | -1.05 | |||||
Net Debt / (EBITDA - Capex) | 1.97 | 2.4 | 2.16 | 2.34 | 2.18 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 194.77 | 49.01 | 24.03 | 49.59 | 15.33 | |||||
Gross Profit, 1 Yr. Growth % | 152.63 | -69.79 | -34.68 | -117.51 | 189.77 | |||||
EBITDA, 1 Yr. Growth % | 133.4 | -42.89 | -7.22 | -26.47 | -20.66 | |||||
EBITA, 1 Yr. Growth % | 132.03 | -42.27 | -6.93 | -25.79 | -19.86 | |||||
EBIT, 1 Yr. Growth % | 131.96 | -42.24 | -6.87 | -25.08 | -18.67 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 161.98 | -37.08 | -24.51 | -23.17 | -31.73 | |||||
Net Income, 1 Yr. Growth % | 161.98 | -37.08 | -24.51 | -23.17 | -31.73 | |||||
Normalized Net Income, 1 Yr. Growth % | 156.54 | -37.04 | -20.01 | -27.75 | -29.66 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 118.81 | -38.92 | -25.16 | -24.96 | -38.32 | |||||
Accounts Receivable, 1 Yr. Growth % | 961.16 | -11.38 | 34.51 | 36.85 | 32.29 | |||||
Inventory, 1 Yr. Growth % | 44.18 | 66.86 | 41.76 | -11.05 | 87.45 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 22.25 | 35.06 | -11.37 | 1.28 | -4.2 | |||||
Total Assets, 1 Yr. Growth % | 24.07 | -24.21 | -15.07 | 14.42 | -1.13 | |||||
Tangible Book Value, 1 Yr. Growth % | 18.14 | -24.31 | -24.83 | 0.3 | -18.6 | |||||
Common Equity, 1 Yr. Growth % | 18.01 | -24.23 | -23.86 | 5.62 | -14.91 | |||||
Cash From Operations, 1 Yr. Growth % | 154.21 | -33.06 | -46.09 | 8.42 | -29.82 | |||||
Capital Expenditures, 1 Yr. Growth % | 80.6 | 34.38 | -70.67 | -21.56 | 43.2 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 200.59 | -24.16 | -66.69 | 245.92 | -71.97 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 200.87 | -24.16 | -66.69 | 245.17 | -72.84 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 233.37 | 109.58 | 35.95 | 36.21 | 31.35 | |||||
Gross Profit, 2 Yr. CAGR % | 90.23 | -12.64 | -55.58 | -66.19 | -28.78 | |||||
EBITDA, 2 Yr. CAGR % | 86.49 | 15.46 | -27.2 | -17.4 | -23.62 | |||||
EBITA, 2 Yr. CAGR % | 85.69 | 15.74 | -26.7 | -16.9 | -22.88 | |||||
EBIT, 2 Yr. CAGR % | 85.61 | 15.75 | -26.66 | -16.47 | -21.94 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 90.04 | 28.39 | -31.08 | -23.84 | -27.57 | |||||
Net Income, 2 Yr. CAGR % | 90.04 | 28.39 | -31.08 | -23.84 | -27.57 | |||||
Normalized Net Income, 2 Yr. CAGR % | 88.05 | 27.09 | -29.04 | -23.98 | -28.71 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 58.11 | 15.6 | -32.39 | -25.06 | -31.97 | |||||
Accounts Receivable, 2 Yr. CAGR % | 280.23 | 206.66 | 9.18 | 35.68 | 34.55 | |||||
Inventory, 2 Yr. CAGR % | 77.65 | 55.1 | 53.8 | 12.3 | 29.13 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 25.42 | 28.49 | 9.41 | -5.25 | -1.5 | |||||
Total Assets, 2 Yr. CAGR % | 112.91 | -3.03 | -19.77 | -1.42 | 6.36 | |||||
Tangible Book Value, 2 Yr. CAGR % | 118.94 | -5.44 | -24.57 | -13.17 | -9.65 | |||||
Common Equity, 2 Yr. CAGR % | 116.41 | -5.44 | -24.05 | -10.32 | -5.2 | |||||
Cash From Operations, 2 Yr. CAGR % | 69.57 | 30.45 | -39.93 | -23.55 | -12.77 | |||||
Capital Expenditures, 2 Yr. CAGR % | 74.11 | 55.79 | -37.21 | -52.03 | 5.98 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 65.18 | 50.99 | -49.74 | 7.34 | -1.53 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 65.29 | 51.06 | -49.74 | 7.23 | -3.18 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 938.1 | 154.89 | 75.96 | 40.35 | 28.86 | |||||
Gross Profit, 3 Yr. CAGR % | 1.68K | 3.02 | -20.71 | -67.43 | -30.8 | |||||
EBITDA, 3 Yr. CAGR % | 70.43 | 25.7 | 7.34 | -26.96 | -18.5 | |||||
EBITA, 3 Yr. CAGR % | 70.26 | 25.79 | 7.63 | -26.4 | -17.89 | |||||
EBIT, 3 Yr. CAGR % | 70.29 | 25.78 | 7.66 | -26.14 | -17.21 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 71.74 | 31.47 | 7.56 | -28.54 | -26.57 | |||||
Net Income, 3 Yr. CAGR % | 71.74 | 31.47 | 7.56 | -28.54 | -26.57 | |||||
Normalized Net Income, 3 Yr. CAGR % | 70.54 | 30.58 | 8.91 | -28.61 | -25.92 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 42.04 | 15.15 | 0 | -30 | -29.77 | |||||
Accounts Receivable, 3 Yr. CAGR % | 747.62 | 134 | 133 | 17.72 | 34.54 | |||||
Inventory, 3 Yr. CAGR % | 1.58K | 73.98 | 50.52 | 28.14 | 33.21 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 40.87 | 28.55 | 13.53 | 6.63 | -4.9 | |||||
Total Assets, 3 Yr. CAGR % | 74.69 | 50.89 | -7.22 | -9.69 | -1.32 | |||||
Tangible Book Value, 3 Yr. CAGR % | 76.14 | 53.66 | -12.4 | -17.06 | -15.02 | |||||
Common Equity, 3 Yr. CAGR % | 76.48 | 52.53 | -12.03 | -15.22 | -11.88 | |||||
Cash From Operations, 3 Yr. CAGR % | 77.91 | 24.39 | -2.84 | -26.86 | -25.7 | |||||
Capital Expenditures, 3 Yr. CAGR % | 22.24 | 59.71 | -10.71 | -32.38 | -30.93 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 88.24 | 27.43 | -8.77 | -4.4 | -31.39 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 88.26 | 27.49 | -8.74 | -4.46 | -32.16 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 360.36 | 98.38 | 56.54 | |||||
Gross Profit, 5 Yr. CAGR % | - | - | 306.08 | -34.02 | -24.04 | |||||
EBITDA, 5 Yr. CAGR % | 78.45 | 50.77 | 21.27 | 6.27 | -6.32 | |||||
EBITA, 5 Yr. CAGR % | 78.57 | 51.03 | 21.54 | 6.57 | -5.81 | |||||
EBIT, 5 Yr. CAGR % | 78.6 | 51.07 | 21.58 | 6.78 | -5.34 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 79.78 | 54.48 | 19.2 | 5.68 | -8.18 | |||||
Net Income, 5 Yr. CAGR % | 79.78 | 54.48 | 19.2 | 5.68 | -8.18 | |||||
Normalized Net Income, 5 Yr. CAGR % | 79.03 | 53.85 | 20.09 | 5.17 | -8.07 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 13.77 | 14.84 | 5.55 | -3.03 | -14.28 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | 273.4 | 88.16 | 87.06 | |||||
Inventory, 5 Yr. CAGR % | - | - | 545.5 | 46.03 | 41.57 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 115.04 | 45.53 | 27.32 | 13.78 | 7.26 | |||||
Total Assets, 5 Yr. CAGR % | 78.47 | 37.35 | 27.97 | 27.27 | -2.01 | |||||
Tangible Book Value, 5 Yr. CAGR % | 92.71 | 34.56 | 25.47 | 22.29 | -11.31 | |||||
Common Equity, 5 Yr. CAGR % | 92.99 | 34.77 | 25.96 | 23.33 | -9.36 | |||||
Cash From Operations, 5 Yr. CAGR % | 76.4 | 62.58 | 15.23 | 2.38 | -6.94 | |||||
Capital Expenditures, 5 Yr. CAGR % | 52.42 | 21.99 | -6.36 | -1.29 | -4.37 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 79.93 | 63.29 | 11 | 18.98 | -5.94 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 79.93 | 63.29 | 11.01 | 18.96 | -6.55 |
- Stock Market
- Stocks
- ZLAB Stock
- Financials Zai Lab Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















